Anzeige
Anzeige

Archive

The effect of decitabine on megakaryocyte maturation and platelet release

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Theme Issue
Platelet function testing: From bench to bedside

DOI: http://dx.doi.org/10.1160/TH10-11-0744
Issue: 2011: 106/2 (Aug) pp. 185-387
Pages: 337-343

The effect of decitabine on megakaryocyte maturation and platelet release

J. Wang (1), Z. Yi (1), S. Wang (1), Z. Li (1)

(1) Department of Medicine, NYU Cancer Institute, New York University School of Medicine, New York, New York, USA

Keywords

Myelodysplastic syndromes, Thrombocytopenia, decitabine

Summary

Thrombocytopenia is a common feature of myelodysplastic syndromes (MDS). 5-aza-2’-deoxycytidine (decitabine) has been used to treat MDS with an approximately 20% response rate in thrombocytopenia. However, the mechanism of how decitabine increases platelet count is not clear. In this study, we investigated the effect of decitabine on megakaryocyte maturation and platelet release in the mouse. The effect of decitabine on megakaryocyte maturation was studied in an in vitro megakaryocyte differentiation model utilising mouse bone marrow cells and mouse megakaryoblastic cell line L8057. Decitabine (2.5 μM) is able to induce L8057 cells to differentiate into a megakaryocyte-like polyploidy cells with positive markers of acetylcholinesterase and αIIb integrin (CD41). Higher expression of αIIb integrin was also found in primary mouse bone marrow cells and human cord blood CD34+ cells cultured with both thrombopoietin and decitabine as compared to thrombopoietin alone. In addition, we noted a 30% platelet count increase in Balb/c mice 12 hours after the injection of decitabine at a clinically relevant dose (15 mg/m2), suggesting a rapid platelet release from the spleen or bone marrow. Our data suggest that decitabine increases platelet counts by enhancing platelet release and megakaryocyte maturation.

You may also be interested in...

1.
Masahito Uemura1*, Yoshihiro Fujimura2*, Masanori Matsumoto 2, Hiromichi Ishizashi 2, Seiji Kato 2, Tomomi Matsuyama 1, Ayami Isonishi 2, Masatoshi Ishikawa 1, Masato Yagita 4, Chie Morioka 1, Hitoshi Yoshiji 1, Tatsuhiro Tsujimoto 1, Norio Kurumatani 3, Hiroshi Fukui1

Thromb Haemost 2008 99 6: 1019-1029

http://dx.doi.org/10.1160/TH08-01-0006

2.
Elizabeth A. Price 1, Catherine P. M. Hayward 2,3, Karen A. Moffat3,4, Jane C. Moore 2,3, Theodore E. Warkentin 2,3, James L. Zehnder1,5

Thromb Haemost 2007 98 6: 1357-1361

http://dx.doi.org/10.1160/TH07-06-0401

3.
Susanne Holzhauer 1, Ana-Gabriela Sitaru 1, 2, Wolfram Ebell 4, Detlev Schindler 5, Helmut Hanenberg 6, Johannes Wirbelauer 1, Ulrich Walter 2, Ralf Grossmann2,3

Thromb Haemost 2007 98 6: 1291-1297

http://dx.doi.org/10.1160/TH07-06-0426